Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18270
Country/Region: Haiti
Year: 2018
Main Partner: Fondation pour la Sante Reproductrice et l'Education Familiale
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $1,700,000 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $301,155
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $86,045
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $172,088
Sexual Prevention: Other Sexual Prevention (HVOP) $557,279
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $282,279
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $301,154
Treatment: Pediatric Treatment (PDTX) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 7
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 10
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 10
GEND_GBV Number of people receiving post-GBV care 2019 10
HTS_SELF 2019 224
HTS_SELF 15-19, Female, Directly-Assisted 2019 8
HTS_SELF 15-19, Female, Unassisted 2019 8
HTS_SELF 15-19, Male, Directly-Assisted 2019 8
HTS_SELF 15-19, Male, Unassisted 2019 8
HTS_SELF 20-24, Female, Directly-Assisted 2019 8
HTS_SELF 20-24, Female, Unassisted 2019 8
HTS_SELF 20-24, Male, Directly-Assisted 2019 8
HTS_SELF 20-24, Male, Unassisted 2019 8
HTS_SELF 25-29, Female, Directly-Assisted 2019 8
HTS_SELF 25-29, Female, Unassisted 2019 8
HTS_SELF 25-29, Male, Directly-Assisted 2019 8
HTS_SELF 25-29, Male, Unassisted 2019 8
HTS_SELF 30-34, Female, Directly-Assisted 2019 8
HTS_SELF 30-34, Female, Unassisted 2019 8
HTS_SELF 30-34, Male, Directly-Assisted 2019 8
HTS_SELF 30-34, Male, Unassisted 2019 8
HTS_SELF 35-39, Female, Directly-Assisted 2019 8
HTS_SELF 35-39, Female, Unassisted 2019 8
HTS_SELF 35-39, Male, Directly-Assisted 2019 8
HTS_SELF 35-39, Male, Unassisted 2019 8
HTS_SELF 40-49, Female, Directly-Assisted 2019 8
HTS_SELF 40-49, Female, Unassisted 2019 8
HTS_SELF 40-49, Male, Directly-Assisted 2019 8
HTS_SELF 40-49, Male, Unassisted 2019 8
HTS_SELF 50+, Female, Directly-Assisted 2019 8
HTS_SELF 50+, Female, Unassisted 2019 8
HTS_SELF 50+, Male, Directly-Assisted 2019 8
HTS_SELF 50+, Male, Unassisted 2019 8
HTS_SELF Directly-Assisted 2019 112
HTS_SELF Unassisted 2019 112
HTS_SELF Unassisted - Other 2019 34
HTS_SELF Unassisted - Self 2019 34
HTS_SELF Unassisted - Sex Partner 2019 44
HTS_TST <5, Unknown Sex, Negative 2019 92
HTS_TST 25-29, Female, Negative 2019 192
HTS_TST 25-29, Female, Negative 2019 43
HTS_TST 25-29, Female, Negative 2019 157
HTS_TST 25-29, Female, Negative 2019 351
HTS_TST 25-29, Female, Negative 2019 2,262
HTS_TST 25-29, Male, Negative 2019 105
HTS_TST 25-29, Male, Negative 2019 22
HTS_TST 25-29, Male, Negative 2019 86
HTS_TST 25-29, Male, Negative 2019 1,251
HTS_TST 30-34, Female, Negative 2019 192
HTS_TST 30-34, Female, Negative 2019 43
HTS_TST 30-34, Female, Negative 2019 157
HTS_TST 30-34, Female, Negative 2019 351
HTS_TST 30-34, Female, Negative 2019 2,262
HTS_TST 30-34, Male, Negative 2019 105
HTS_TST 30-34, Male, Negative 2019 22
HTS_TST 30-34, Male, Negative 2019 86
HTS_TST 30-34, Male, Negative 2019 1,251
HTS_TST 35-39, Female, Negative 2019 192
HTS_TST 35-39, Female, Negative 2019 43
HTS_TST 35-39, Female, Negative 2019 157
HTS_TST 35-39, Female, Negative 2019 352
HTS_TST 35-39, Female, Negative 2019 2,262
HTS_TST 35-39, Male, Negative 2019 105
HTS_TST 35-39, Male, Negative 2019 22
HTS_TST 35-39, Male, Negative 2019 86
HTS_TST 35-39, Male, Negative 2019 1,251
HTS_TST 40-49, Female, Negative 2019 188
HTS_TST 40-49, Female, Negative 2019 42
HTS_TST 40-49, Female, Negative 2019 155
HTS_TST 40-49, Female, Negative 2019 352
HTS_TST 40-49, Female, Negative 2019 2,259
HTS_TST 40-49, Male, Negative 2019 106
HTS_TST 40-49, Male, Negative 2019 27
HTS_TST 40-49, Male, Negative 2019 84
HTS_TST 40-49, Male, Negative 2019 1,248
HTS_TST By Key Population: FSW, Negative 2019 17,586
HTS_TST By Key Population: MSM, Negative 2019 5,863
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 27,619
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 77
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 174
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 271
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 23
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 261
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 81
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 81
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 28
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 14
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 107
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 45
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 166
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 139
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 8
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 98
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 19
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 31
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 5
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 4
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 26
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 16
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 31
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 21
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 22
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 14
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 89
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 41
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 131
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 105
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 689
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 319
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 175
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 1,233
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 479
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 2,033
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 1,746
HTS_TST_POS <5, Unknown Sex, Positive 2019 2
HTS_TST_POS 25-29, Female, Positive 2019 34
HTS_TST_POS 25-29, Female, Positive 2019 3
HTS_TST_POS 25-29, Female, Positive 2019 7
HTS_TST_POS 25-29, Female, Positive 2019 53
HTS_TST_POS 25-29, Male, Positive 2019 19
HTS_TST_POS 25-29, Male, Positive 2019 1
HTS_TST_POS 25-29, Male, Positive 2019 30
HTS_TST_POS 30-34, Female, Positive 2019 34
HTS_TST_POS 30-34, Female, Positive 2019 3
HTS_TST_POS 30-34, Female, Positive 2019 7
HTS_TST_POS 30-34, Female, Positive 2019 53
HTS_TST_POS 30-34, Male, Positive 2019 19
HTS_TST_POS 30-34, Male, Positive 2019 1
HTS_TST_POS 30-34, Male, Positive 2019 30
HTS_TST_POS 35-39, Female, Positive 2019 34
HTS_TST_POS 35-39, Female, Positive 2019 3
HTS_TST_POS 35-39, Female, Positive 2019 6
HTS_TST_POS 35-39, Female, Positive 2019 53
HTS_TST_POS 35-39, Male, Positive 2019 19
HTS_TST_POS 35-39, Male, Positive 2019 1
HTS_TST_POS 35-39, Male, Positive 2019 30
HTS_TST_POS 40-49, Female, Positive 2019 32
HTS_TST_POS 40-49, Female, Positive 2019 3
HTS_TST_POS 40-49, Female, Positive 2019 8
HTS_TST_POS 40-49, Female, Positive 2019 10
HTS_TST_POS 40-49, Female, Positive 2019 51
HTS_TST_POS 40-49, Male, Positive 2019 18
HTS_TST_POS 40-49, Male, Positive 2019 2
HTS_TST_POS 40-49, Male, Positive 2019 4
HTS_TST_POS 40-49, Male, Positive 2019 25
HTS_TST_POS By Key Population: FSW, Positive 2019 601
HTS_TST_POS By Key Population: MSM, Positive 2019 200
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) ANC: 50+, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 20
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 30
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 25
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 29
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 46
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 40
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 25,950
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 6,800
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 32,750
PMTCT_ART Already on ART at beginning of current pregnancy 2019 38
PMTCT_ART New on ART 2019 38
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 76
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 2,020
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 66
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 17
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 83
PMTCT_EID Sum of Infant Age disaggregates 2019 83
PMTCT_STAT 25-29, Female 2019 371
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 9
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 351
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 7
PMTCT_STAT 30-34, Female 2019 370
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 9
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 351
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 7
PMTCT_STAT 35-39, Female 2019 369
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 8
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 352
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 6
PMTCT_STAT 40-49, Female 2019 367
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 11
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 352
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 10
PMTCT_STAT By Age (Numerator): 15-19 2019 79
PMTCT_STAT By Age (Numerator): 20-24 2019 181
PMTCT_STAT By Age (Numerator): 50+ 2019 283
PMTCT_STAT By Number of known positives: 15-19 2019 1
PMTCT_STAT By Number of known positives: 20-24 2019 3
PMTCT_STAT By Number of known positives: 50+ 2019 6
PMTCT_STAT By Number of new negative: 15-19 2019 77
PMTCT_STAT By Number of new negative: 20-24 2019 174
PMTCT_STAT By Number of new negative: 50+ 2019 271
PMTCT_STAT By Number of new positives: 15-19 2019 2
PMTCT_STAT By Number of new positives: 20-24 2019 2
PMTCT_STAT By Number of new positives: 50+ 2019 5
PMTCT_STAT Number of new ANC and L&D clients 2019 2,020
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 2,020
PMTCT_STAT_den 25-29, Female 2019 371
PMTCT_STAT_den 30-34, Female 2019 370
PMTCT_STAT_den 35-39, Female 2019 369
PMTCT_STAT_den 40-49, Female 2019 367
PMTCT_STAT_den By Age (Denominator): <15-19 2019 79
PMTCT_STAT_den By Age (Denominator): 20-24 2019 181
PMTCT_STAT_den By Age (Denominator): 50+ 2019 283
PP_PREV 25-29, Male 2019 2,517
PP_PREV 30-34, Male 2019 2,517
PP_PREV 35-39, Male 2019 2,517
PP_PREV 40-49, Male 2019 2,517
PP_PREV Age/sex: 10-14 Male 2019 45
PP_PREV Age/sex: 15-19 Male 2019 1,085
PP_PREV Age/sex: 20-24 Male 2019 4,603
PP_PREV Age/sex: 50+ Male 2019 599
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2019 16,400
PP_PREV Sum of Age/Sex disaggregates 2019 6,332
PrEP_NEW 25-29, Female 2019 46
PrEP_NEW 25-29, Male 2019 47
PrEP_NEW 30-34, Female 2019 40
PrEP_NEW 30-34, Male 2019 35
PrEP_NEW 35-39, Female 2019 23
PrEP_NEW 35-39, Male 2019 19
PrEP_NEW 40-49, Female 2019 15
PrEP_NEW 40-49, Male 2019 12
PrEP_NEW Female 15-19 2019 9
PrEP_NEW Female 20-24 2019 32
PrEP_NEW Female 50+ 2019 7
PrEP_NEW FSW 2019 172
PrEP_NEW Male 15-19 2019 8
PrEP_NEW Male 20-24 2019 31
PrEP_NEW Male 50+ 2019 6
PrEP_NEW MSM 2019 153
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 330
PrEP_NEW Other Key Populations 2019 5
TB_PREV By Age/Sex (Numerator): <15, Female 2019 29
TB_PREV By Age/Sex (Numerator): <15, Male 2019 20
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 591
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 346
TB_PREV IPT, Life-long ART, New, Positive 2019 986
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 986
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 1,093
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 32
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 22
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 656
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 383
TB_PREV_den IPT, Life-long ART, New, Positive 2019 1,093
TX_CURR 25-29, Female, Positive 2019 405
TX_CURR 25-29, Male, Positive 2019 216
TX_CURR 30-34, Female, Positive 2019 405
TX_CURR 30-34, Male, Positive 2019 216
TX_CURR 35-39, Female, Positive 2019 405
TX_CURR 35-39, Male, Positive 2019 216
TX_CURR 40-49, Female, Positive 2019 405
TX_CURR 40-49, Male, Positive 2019 216
TX_CURR Age/Sex: <1 2019 4
TX_CURR Age/Sex: <1-9 2019 44
TX_CURR Age/Sex: 10-14 Female 2019 14
TX_CURR Age/Sex: 10-14 Male 2019 14
TX_CURR Age/Sex: 15-19 Female 2019 59
TX_CURR Age/Sex: 15-19 Male 2019 32
TX_CURR Age/Sex: 20-24 Female 2019 223
TX_CURR Age/Sex: 20-24 Male 2019 100
TX_CURR Age/Sex: 50+ Female 2019 331
TX_CURR Age/Sex: 50+ Male 2019 267
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 3,572
TX_CURR Sum of age/sex disaggregates 2019 91
TX_NEW 25-29, Female, Positive 2019 114
TX_NEW 25-29, Male, Positive 2019 63
TX_NEW 30-34, Female, Positive 2019 108
TX_NEW 30-34, Male, Positive 2019 59
TX_NEW 35-39, Female, Positive 2019 108
TX_NEW 35-39, Male, Positive 2019 59
TX_NEW 40-49, Female, Positive 2019 108
TX_NEW 40-49, Male, Positive 2019 59
TX_NEW Breastfeeding status 2019 11
TX_NEW By Age/Sex: <1 2019 1
TX_NEW By Age/Sex: 1-9 2019 15
TX_NEW By Age/Sex: 10-14 Female 2019 5
TX_NEW By Age/Sex: 10-14 Male 2019 5
TX_NEW By Age/Sex: 15-19 Female 2019 13
TX_NEW By Age/Sex: 15-19 Male 2019 7
TX_NEW By Age/Sex: 20-24 Female 2019 66
TX_NEW By Age/Sex: 20-24 Male 2019 30
TX_NEW By Age/Sex: 50+ Female 2019 93
TX_NEW By Age/Sex: 50+ Male 2019 79
TX_NEW FSW 2019 394
TX_NEW MSM 2019 578
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 992
TX_NEW Pregnancy status 2019 38
TX_NEW Sum of Age/Sex disaggregates 2019 298
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 2,995
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 81
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 9
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 54
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 6
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 1,618
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 179
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 944
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 104
TX_PVLS_den Denominator: Indication: Routine 2019 2,697
TX_PVLS_den Denominator: Indication: Targeted 2019 298
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 35
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 24
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 687
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 401
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 1,147
TX_RET Numerator by Status: Breastfeeding 2019 13
TX_RET Numerator by Status: Pregnant 2019 116
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 1,147
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 35
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 24
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 687
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 401
TX_RET_den Denominator by Status: Breastfeeding 2019 13
TX_RET_den Denominator by Status: Pregnant 2019 116
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 3,215
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 97
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 65
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 1,927
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 1,126
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 52
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2019 5
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 72
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 129
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 2,499
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 105
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 586
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 24
Cross Cutting Budget Categories and Known Amounts Total: $1,750,000
Key Populations: MSM and TG $753,124
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Monitoring and evaluation of MSM/TG programs
Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Key Populations: Sex Workers $946,876
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Gender: Gender Based Violence (GBV) $50,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Monitoring and Evaluation